bearish
Celltrion (068270 KS): Increasing Biosimilar Competition- Main Concerning Factor
270 Views09 Mar 2022 00:56
SUMMARY
- Fierce competition is an industry-wide phenomena in biosimilar products. Despite being an early mover, Celltrion Inc (068270 KS) is also facing competition for its marketed biosimilars.
- The market share of Celltrion’s key biosimilar product, Remsima is declining. Other marketed and upcoming biosimilars also have multiple existing players.
- With the waning COVID-19 infections in the U.S., demand for Celltrion’s rapid test kits seems uncertain.
Begin exploring Smartkarma's AI-augmented investing intelligence platform with a complimentary Preview Pass to:
- Unlock research summaries
- Follow top, independent analysts
- Receive personalised alerts
- Access Analytics, Events and more
Join 55,000+ investors, including top global asset managers overseeing $13+ trillion.
Upgrade later to our paid plans for full-access.
or
Already have an account? Sign In Now
Discussions
(Paid Plans Only)
Rising
Tina Banerjee
Global Healthcare Analyst
Price Chart(Sign Up to Access)
- Celltrion Group Companies - Sharp Increase in Dividends17 Dec 2022
- Celltrion (068270 KS): Competition Makes US Approval of New Oncology Biosimilar Unappealing30 Sep 2022
- Celltrion (068270 KS): Muted Q1 2022 Performance Reflects Continuing Biosimilars Pricing Pressure14 May 2022
- FSC Finally Reviews Accounting Fraud Allegations of Celltrion Group After 3 Years of Investigation23 Nov 2021
- Celltrion Inc - The Minority Shareholders Upheaval & Concerns About Potential Inheritance Tax Issue15 Oct 2021
x